<DOC>
	<DOC>NCT02663141</DOC>
	<brief_summary>The aim of this study is to determine whether oral losartan is effective in the treatment of diabetic macular edema (DME) as an adjuvant for intravitreal bevacizumab (IVB).</brief_summary>
	<brief_title>Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>All type 2 diabetes mellitus patients with clinically significant macular edema(CSME), except those mentioned as exclusion criteria 1. Patients with Uncontrolled hypertension 2. Patients with Proliferative diabetic retinopathy 3. Patients Who received angiotensin converting enzyme inhibitor(ACEI) or angiotensin receptor blocker(ARB) 4. Previous treatment for diabetic retinopathy (e.g., laser photocoagulation, photodynamic therapy, intravitreal injections of steroids, or antivascular endothelial growth factor, retinal surgery) 5. media opacities 6. evidence of any other ocular disease(e.g., glaucoma, uveitis, age related macular degeneration or etc.,) 7. Pathologic myopia &gt; 6 Diopter 8. Patients with poor fixation or cooperation 9. Patients with renal or cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>